Comparative pathology of experimental pulmonary tuberculosis in animal models.

Laura Hunter, Inés Ruedas-Torres, Irene Agulló-Ros, Emma Rayner, Francisco J Salguero
Author Information
  1. Laura Hunter: Pathology Department, UK Health Security Agency (UKHSA), Porton Down, Salisbury, United Kingdom.
  2. Inés Ruedas-Torres: Pathology Department, UK Health Security Agency (UKHSA), Porton Down, Salisbury, United Kingdom.
  3. Irene Agulló-Ros: Pathology Department, UK Health Security Agency (UKHSA), Porton Down, Salisbury, United Kingdom.
  4. Emma Rayner: Pathology Department, UK Health Security Agency (UKHSA), Porton Down, Salisbury, United Kingdom.
  5. Francisco J Salguero: Pathology Department, UK Health Security Agency (UKHSA), Porton Down, Salisbury, United Kingdom.

Abstract

Research in human tuberculosis (TB) is limited by the availability of human tissues from patients, which is often altered by therapy and treatment. Thus, the use of animal models is a key tool in increasing our understanding of the pathogenesis, disease progression and preclinical evaluation of new therapies and vaccines. The granuloma is the hallmark lesion of pulmonary tuberculosis, regardless of the species or animal model used. Although animal models may not fully replicate all the histopathological characteristics observed in natural, human TB disease, each one brings its own attributes which enable researchers to answer specific questions regarding TB immunopathogenesis. This review delves into the pulmonary pathology induced by complex (MTBC) bacteria in different animal models (non-human primates, rodents, guinea pigs, rabbits, cattle, goats, and others) and compares how they relate to the pulmonary disease described in humans. Although the described models have demonstrated some histopathological features in common with human pulmonary TB, these data should be considered carefully in the context of this disease. Further research is necessary to establish the most appropriate model for the study of TB, and to carry out a standard characterisation and score of pulmonary lesions.

Keywords

References

  1. Vaccines (Basel). 2021 Aug 25;9(9): [PMID: 34579182]
  2. J Pathol. 2006 Jan;208(2):261-9 [PMID: 16362982]
  3. BMC Microbiol. 2011 Mar 04;11:49 [PMID: 21375756]
  4. Dis Model Mech. 2015 Jun;8(6):603-10 [PMID: 26035868]
  5. PLoS One. 2010 Jun 14;5(6):e11108 [PMID: 20559431]
  6. J Exp Med. 1932 Jan 1;55(1):31-54 [PMID: 19869977]
  7. PLoS One. 2019 Jul 15;14(7):e0218547 [PMID: 31306432]
  8. Dis Model Mech. 2011 Jul;4(4):526-36 [PMID: 21372049]
  9. J Comp Pathol. 2015 Feb-Apr;152(2-3):217-26 [PMID: 25481611]
  10. Vet Immunol Immunopathol. 2016 Nov 1;180:34-39 [PMID: 27692093]
  11. Elife. 2020 Nov 24;9: [PMID: 33228849]
  12. Vet Pathol. 2013 May;50(3):488-99 [PMID: 23169912]
  13. Cell Microbiol. 2006 Feb;8(2):218-32 [PMID: 16441433]
  14. Virulence. 2022 Dec;13(1):1543-1557 [PMID: 36052440]
  15. Vet Pathol. 2019 Jul;56(4):544-554 [PMID: 30895908]
  16. Res Vet Sci. 2014 Oct;97 Suppl:S20-9 [PMID: 24731532]
  17. Microbes Infect. 2006 Sep;8(11):2587-98 [PMID: 16952476]
  18. Thorax. 2016 Dec;71(12):1145-1153 [PMID: 27245780]
  19. Front Vet Sci. 2021 May 07;8:671460 [PMID: 34026898]
  20. J Med Microbiol. 2011 May;60(Pt 5):661-669 [PMID: 21233296]
  21. J Antivir Antiretrovir. 2014 Mar 3;6:40-42 [PMID: 25635205]
  22. Tuberculosis (Edinb). 2008 Jul;88(4):295-306 [PMID: 18321783]
  23. Vet Res Commun. 2022 Dec;46(4):1147-1156 [PMID: 36136210]
  24. Eur Respir Rev. 2018 Feb 28;27(147): [PMID: 29491034]
  25. PLoS One. 2011 Apr 12;6(4):e18632 [PMID: 21533270]
  26. Front Immunol. 2016 May 19;7:196 [PMID: 27242801]
  27. Nature. 2005 Apr 7;434(7034):767-72 [PMID: 15815631]
  28. Semin Immunopathol. 2016 Mar;38(2):261-73 [PMID: 26324465]
  29. Cell Microbiol. 2008 May;10(5):1027-39 [PMID: 18298637]
  30. Vet J. 2008 Mar;175(3):409-12 [PMID: 17584504]
  31. Microbiol Spectr. 2016 Aug;4(4): [PMID: 27726820]
  32. Vaccine. 2011 May 12;29(21):3782-90 [PMID: 21440035]
  33. Int J Mol Sci. 2023 Mar 14;24(6): [PMID: 36982586]
  34. Pathogens. 2022 Jan 04;11(1): [PMID: 35056009]
  35. Nat Rev Drug Discov. 2005 Jan;4(1):35-44 [PMID: 15688071]
  36. J Comp Pathol. 1998 Jul;119(1):27-44 [PMID: 9717125]
  37. Res Vet Sci. 2016 Oct;108:116-9 [PMID: 27663379]
  38. Scand J Immunol. 2000 Aug;52(2):156-63 [PMID: 10931383]
  39. J Comp Pathol. 2005 Nov;133(4):223-34 [PMID: 16154140]
  40. PLoS One. 2010 Apr 06;5(4):e10030 [PMID: 20386605]
  41. FEMS Microbiol Lett. 2003 Aug 29;225(2):177-82 [PMID: 12951238]
  42. Infect Immun. 2004 Mar;72(3):1700-5 [PMID: 14977978]
  43. J Infect Dis. 1998 Jun;177(6):1563-72 [PMID: 9607834]
  44. Tuberculosis (Edinb). 2003;83(1-3):131-4 [PMID: 12758202]
  45. PLoS Pathog. 2021 Mar 15;17(3):e1009410 [PMID: 33720986]
  46. Antimicrob Agents Chemother. 2007 Sep;51(9):3338-45 [PMID: 17517834]
  47. PLoS One. 2017 Jul 5;12(7):e0180546 [PMID: 28678885]
  48. Sci Rep. 2018 Jan 17;8(1):894 [PMID: 29343690]
  49. J Comp Pathol. 2013 Nov;149(4):475-85 [PMID: 23880551]
  50. J Infect Dis. 2012 Feb 15;205(4):595-602 [PMID: 22198962]
  51. Vet Pathol. 2007 Nov;44(6):863-74 [PMID: 18039899]
  52. Vaccine. 2018 Jul 16;36(30):4447-4453 [PMID: 29935860]
  53. Am J Pathol. 2018 Jul;188(7):1666-1675 [PMID: 29753789]
  54. Curr Opin Immunol. 2011 Aug;23(4):464-72 [PMID: 21726990]
  55. PLoS Pathog. 2012 Sep;8(9):e1002944 [PMID: 23028333]
  56. Transbound Emerg Dis. 2013 Apr;60(2):102-9 [PMID: 22469036]
  57. Tuberculosis (Edinb). 2013 Sep;93(5):558-64 [PMID: 23850102]
  58. Cold Spring Harb Perspect Med. 2014 Nov 20;5(3):a018580 [PMID: 25414379]
  59. Nat Med. 2016 May;22(5):531-8 [PMID: 27043495]
  60. Nat Rev Immunol. 2012 Apr 20;12(5):352-66 [PMID: 22517424]
  61. Nat Med. 1996 Apr;2(4):430-6 [PMID: 8597953]
  62. Curr Protoc. 2021 Dec;1(12):e312 [PMID: 34941021]
  63. Infect Immun. 2003 Oct;71(10):5831-44 [PMID: 14500505]
  64. Transbound Emerg Dis. 2013 Dec;60(6):525-37 [PMID: 22909117]
  65. Front Microbiol. 2022 Nov 08;13:1048648 [PMID: 36425039]
  66. J Immunol. 2007 Aug 15;179(4):2532-41 [PMID: 17675515]
  67. Tuberculosis (Edinb). 2016 Dec;101:174-190 [PMID: 27865390]
  68. J Pathol. 2005 Apr;205(5):633-40 [PMID: 15776475]
  69. Immunity. 2002 Dec;17(6):693-702 [PMID: 12479816]
  70. Front Immunol. 2022 Mar 07;13:820134 [PMID: 35320930]
  71. Clin Dev Immunol. 2012;2012:139127 [PMID: 22811737]
  72. Infect Immun. 2002 Jun;70(6):3026-32 [PMID: 12010994]
  73. Tuberculosis (Edinb). 2016 Jan;96:141-9 [PMID: 26723465]
  74. Am J Pathol. 2012 Aug;181(2):508-14 [PMID: 22721647]
  75. Pathogens. 2022 Jun 04;11(6): [PMID: 35745503]
  76. Infect Immun. 2006 Sep;74(9):5397-401 [PMID: 16926435]
  77. Cell Microbiol. 2006 Apr;8(4):661-7 [PMID: 16548891]
  78. PLoS One. 2013;8(1):e53884 [PMID: 23326525]
  79. Infect Immun. 2013 Aug;81(8):2909-19 [PMID: 23716617]
  80. J Fish Dis. 2018 Oct;41(10):1515-1528 [PMID: 29956837]
  81. Microbiol Spectr. 2017 Jan;5(1): [PMID: 28155806]
  82. Front Vet Sci. 2023 Sep 22;10:1264200 [PMID: 37808110]
  83. Tuberculosis (Edinb). 2007 Jul;87(4):267-78 [PMID: 17369095]
  84. Dis Model Mech. 2015 Jun;8(6):591-602 [PMID: 26035867]
  85. Int J Exp Pathol. 2004 Jun;85(3):125-34 [PMID: 15255966]
  86. Am J Clin Pathol. 1990 Sep;94(3):307-12 [PMID: 1697733]
  87. Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S35-47 [PMID: 18762152]
  88. Infect Immun. 2009 Oct;77(10):4631-42 [PMID: 19620341]
  89. Front Immunol. 2019 Jan 31;10:89 [PMID: 30766535]
  90. Infect Immun. 1996 Nov;64(11):4776-87 [PMID: 8890239]
  91. Immunology. 1996 Sep;89(1):26-33 [PMID: 8911136]
  92. Lancet Microbe. 2020 Jun;1(2):e66-e73 [PMID: 32642742]
  93. Infect Immun. 2001 Mar;69(3):1722-8 [PMID: 11179349]
  94. Tuberculosis (Edinb). 2005 May;85(3):177-84 [PMID: 15850755]
  95. Annu Rev Microbiol. 2003;57:641-76 [PMID: 14527294]
  96. Infect Immun. 2006 Nov;74(11):6108-17 [PMID: 17057088]
  97. Pathology. 1987 Apr;19(2):186-92 [PMID: 3453999]
  98. Tuber Lung Dis. 1997;78(1):57-66 [PMID: 9666963]
  99. Virulence. 2018;9(1):1126-1137 [PMID: 30067135]
  100. Infect Immun. 2002 Nov;70(11):6330-8 [PMID: 12379712]
  101. Fish Shellfish Immunol. 2016 Oct;57:79-86 [PMID: 27539703]
  102. Open Biol. 2011 Dec;1(4):110016 [PMID: 22645653]
  103. Clin Vaccine Immunol. 2011 Nov;18(11):1872-81 [PMID: 21880849]
  104. Front Vet Sci. 2022 May 03;9:877322 [PMID: 35591868]
  105. J Comp Pathol. 2011 Jan;144(1):1-24 [PMID: 21131004]
  106. Comp Immunol Microbiol Infect Dis. 2018 Oct;60:28-34 [PMID: 30396427]
  107. Infect Immun. 2008 Jun;76(6):2333-40 [PMID: 18347040]
  108. Tuberculosis (Edinb). 2007 Mar;87(2):145-54 [PMID: 16973421]
  109. Vet Res. 2019 Oct 15;50(1):82 [PMID: 31615555]
  110. Vet Immunol Immunopathol. 2010 Feb 15;133(2-4):269-75 [PMID: 19716181]
  111. Antimicrob Agents Chemother. 2012 Jun;56(6):3181-95 [PMID: 22470120]
  112. EMBO Mol Med. 2010 Jul;2(7):258-74 [PMID: 20597103]
  113. Vet Immunol Immunopathol. 2012 Sep 15;149(1-2):66-75 [PMID: 22763148]
  114. Int J Mol Sci. 2022 Sep 20;23(19): [PMID: 36232295]
  115. Vet Pathol. 2002 May;39(3):334-40 [PMID: 12014497]
  116. Front Cell Infect Microbiol. 2017 Jan 24;7:6 [PMID: 28174695]
  117. Vet Immunol Immunopathol. 2013 Nov 15;156(1-2):54-63 [PMID: 24144683]
  118. J Comp Pathol. 2001 Jan;124(1):46-51 [PMID: 11428188]
  119. Front Immunol. 2022 Jan 06;12:776913 [PMID: 35069548]
  120. Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):277-93 [PMID: 16249122]
  121. Infect Immun. 2003 Feb;71(2):864-71 [PMID: 12540568]
  122. Infect Immun. 2006 Jul;74(7):3790-803 [PMID: 16790751]
  123. Infect Immun. 2003 Dec;71(12):7023-34 [PMID: 14638792]
  124. Biomed Res Int. 2020 Jan 2;2020:4263079 [PMID: 32025519]
  125. NPJ Vaccines. 2021 Jan 4;6(1):4 [PMID: 33397991]
  126. Respiration. 2021;100(7):557-567 [PMID: 33321506]
  127. Cold Spring Harb Perspect Med. 2014 Dec 18;5(5):a018572 [PMID: 25524720]
  128. Dis Model Mech. 2020 Aug 23;13(8): [PMID: 32859577]
  129. Semin Immunol. 2014 Dec;26(6):601-9 [PMID: 25453231]
  130. Front Vet Sci. 2020 Feb 04;7:41 [PMID: 32118064]
  131. Tuberculosis (Edinb). 2013 Dec;93 Suppl:S51-9 [PMID: 24388650]
  132. J Comp Pathol. 2011 Aug-Oct;145(2-3):107-17 [PMID: 21334000]
  133. J Exp Med. 1929 Nov 30;50(6):747-65 [PMID: 19869661]
  134. Infect Immun. 2018 Aug 22;86(9): [PMID: 29891540]
  135. Transbound Emerg Dis. 2017 Dec;64(6):1734-1749 [PMID: 27615603]
  136. Infect Immun. 2003 Oct;71(10):6004-11 [PMID: 14500521]
  137. Antimicrob Agents Chemother. 2014 Jul;58(7):4026-34 [PMID: 24798275]
  138. Microbiol Spectr. 2017 Jun;5(3): [PMID: 28597826]
  139. Tuberculosis (Edinb). 2009 Nov;89(6):405-16 [PMID: 19879805]
  140. Crit Rev Microbiol. 2018 Nov;44(6):779-792 [PMID: 30663918]
  141. Adv Exp Med Biol. 2013;783:251-66 [PMID: 23468113]
  142. Microbes Infect. 2006 Apr;8(4):1179-88 [PMID: 16513383]
  143. J Pathol. 2004 Oct;204(2):217-28 [PMID: 15376257]
  144. Mol Microbiol. 2022 Mar;117(3):661-669 [PMID: 34714579]

Word Cloud

Created with Highcharts 10.0.0animalmodelspulmonaryTBhumantuberculosisdiseasepathologygranulomamodelAlthoughhistopathologicaldescribedResearchlimitedavailabilitytissuespatientsoftenalteredtherapytreatmentThususekeytoolincreasingunderstandingpathogenesisprogressionpreclinicalevaluationnewtherapiesvaccineshallmarklesionregardlessspeciesusedmayfullyreplicatecharacteristicsobservednaturalonebringsattributesenableresearchersanswerspecificquestionsregardingimmunopathogenesisreviewdelvesinducedcomplexMTBCbacteriadifferentnon-humanprimatesrodentsguineapigsrabbitscattlegoatsotherscomparesrelatehumansdemonstratedfeaturescommondataconsideredcarefullycontextresearchnecessaryestablishappropriatestudycarrystandardcharacterisationscorelesionsComparativeexperimentallungmycobacteria

Similar Articles

Cited By